{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:48:07Z","timestamp":1789382887303,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ccl.2018.08.008","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T18:54:30Z","timestamp":1541012070000},"page":"113-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel Pharmacotherapy for Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"37","author":[{"given":"Timothy C.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.ccl.2018.08.008_bib1","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of cardiology foundation\/American heart association task force on practice guidelines","volume":"124","author":"Gersh","year":"2011","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ccl.2018.08.008_bib2","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.01.023","article-title":"Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy","volume":"67","author":"Maron","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.ccl.2018.08.008_bib3","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/CIRCULATIONAHA.110.950089","article-title":"Research priorities in hypertrophic cardiomyopathy: report of a working group of the National Heart, lung, and blood institute","volume":"122","author":"Force","year":"2010","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ccl.2018.08.008_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"39","key":"10.1016\/j.ccl.2018.08.008_bib5","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.ccl.2018.08.008_bib6","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCRESAHA.117.312647","article-title":"Hypertrophy regression with n-acetylcysteine in hypertrophic cardiomyopathy (HALT-HCM)novelty and significance","volume":"122","author":"Marian","year":"2018","journal-title":"Circ Res"},{"issue":"10","key":"10.1016\/j.ccl.2018.08.008_bib7","doi-asserted-by":"crossref","first-page":"H1720","DOI":"10.1152\/ajpheart.00339.2015","article-title":"N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy","volume":"309","author":"Wilder","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"16","key":"10.1016\/j.ccl.2018.08.008_bib8","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archinte.164.16.1737","article-title":"Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart","volume":"164","author":"Lim","year":"2004","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.ccl.2018.08.008_bib9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00439-007-0429-9","article-title":"RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy","volume":"122","author":"Kaufman","year":"2007","journal-title":"Hum Genet"},{"issue":"14","key":"10.1016\/j.ccl.2018.08.008_bib10","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1161\/01.CIR.97.14.1342","article-title":"Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy","volume":"97","author":"Kyriakidis","year":"1998","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ccl.2018.08.008_bib11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1253\/circj.69.1244","article-title":"Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy","volume":"69","author":"Kawano","year":"2005","journal-title":"Circ J"},{"issue":"6","key":"10.1016\/j.ccl.2018.08.008_bib12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1536\/ihj.48.715","article-title":"A\u00a0new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker","volume":"48","author":"Yamazaki","year":"2007","journal-title":"Int Heart J"},{"issue":"1","key":"10.1016\/j.ccl.2018.08.008_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2353\/jmoldx.2009.080082","article-title":"The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy","volume":"11","author":"Penicka","year":"2009","journal-title":"J\u00a0Mol Diagn"},{"issue":"11","key":"10.1016\/j.ccl.2018.08.008_bib14","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.amjcard.2005.07.065","article-title":"Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy","volume":"96","author":"Araujo","year":"2005","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.ccl.2018.08.008_bib15","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/01.CIR.0000121426.43044.2B","article-title":"Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy","volume":"109","author":"Tsybouleva","year":"2004","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ccl.2018.08.008_bib16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.amjmed.2018.02.025","article-title":"Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.ccl.2018.08.008_bib17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1172\/JCI200214677","article-title":"The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model","volume":"109","author":"Semsarian","year":"2002","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.ccl.2018.08.008_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jchf.2014.08.003","article-title":"Diltiazem treatment for pre-Clinical hypertrophic cardiomyopathy sarcomere Mutation carriers: a pilot randomized trial to modify disease expression","volume":"3","author":"Ho","year":"2015","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.ccl.2018.08.008_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/01.CIR.104.3.317","article-title":"Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy","volume":"104","author":"Patel","year":"2001","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ccl.2018.08.008_bib20","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1365-2362.2010.02349.x","article-title":"Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study","volume":"40","author":"Nagueh","year":"2010","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"10.1016\/j.ccl.2018.08.008_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/1995-705X.201784","article-title":"Statin induced regression of cardiomyopathy trial: a randomized, placebo-controlled double-blind trial","volume":"17","author":"Hersi","year":"2016","journal-title":"Heart Views"},{"issue":"16","key":"10.1016\/j.ccl.2018.08.008_bib22","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","article-title":"Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy","volume":"122","author":"Abozguia","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccl.2018.08.008_bib23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2018.08.008_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCHEARTFAILURE.116.003565","article-title":"Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy","volume":"10","author":"Coppini","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"16","key":"10.1016\/j.ccl.2018.08.008_bib25","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2016.07.758","article-title":"Ranolazine for treatment of angina or dyspnea in hypertrophic cardiomyopathy patients (RHYME)","volume":"68","author":"Gentry","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ccl.2018.08.008_bib26","first-page":"525","article-title":"Hemodynamic effects on intravenous propafenone in hypertrophic myocardiopathy","volume":"81","author":"Funck","year":"1988","journal-title":"Arch Mal Coeur Vaiss"},{"issue":"3","key":"10.1016\/j.ccl.2018.08.008_bib27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.acvd.2015.11.005","article-title":"Midodrine hydrochloride and unexpected improvement in hypertrophic cardiomyopathy symptoms","volume":"109","author":"Lafitte","year":"2016","journal-title":"Arch Cardiovasc Dis"},{"issue":"11","key":"10.1016\/j.ccl.2018.08.008_bib28","doi-asserted-by":"crossref","first-page":"e28134","DOI":"10.1371\/journal.pone.0028134","article-title":"In\u00a0vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion","volume":"6","author":"Shi","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ccl.2018.08.008_bib29","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrd3431","article-title":"Novel therapeutic targets for the treatment of heart failure","volume":"10","author":"Tamargo","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.ccl.2018.08.008_bib30","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/sj.bjp.0701643","article-title":"Effect of trimetazidine and verapamil on the cardiomyopathic hamster myosin phenotype","volume":"123","author":"D\u2019hahan","year":"1998","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.ccl.2018.08.008_bib31","first-page":"1","article-title":"Novel\u00a0approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) trial","volume":"9","author":"Olivotto","year":"2016","journal-title":"Circ Hear Fail"},{"issue":"19","key":"10.1016\/j.ccl.2018.08.008_bib32","doi-asserted-by":"crossref","first-page":"9005","DOI":"10.1021\/acs.jmedchem.6b00939","article-title":"Discovery of dihydrobenzoxazepinone (GS-6615) late sodium current inhibitor (late I Na i), a phase II agent with demonstrated preclinical anti-ischemic and antiarrhythmic properties","volume":"59","author":"Zablocki","year":"2016","journal-title":"J\u00a0Med Chem"},{"issue":"40","key":"10.1016\/j.ccl.2018.08.008_bib33","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A\u00a0small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J\u00a0Biol Chem"},{"issue":"6273","key":"10.1016\/j.ccl.2018.08.008_bib34","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"Heart disease: a small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ccl.2018.08.008_bib35","unstructured":"MyoKardia Press Release. Press release. 2018.\u00a0Available at: http:\/\/investors.myokardia.com\/phoenix.zhtml?c=254211&p=irol-newsArticle&ID=2337154%0AWC%0A. Accessed June 8, 2018."},{"issue":"7668","key":"10.1016\/j.ccl.2018.08.008_bib36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23305","article-title":"Correction of a pathogenic gene mutation in human embryos","volume":"548","author":"Ma","year":"2017","journal-title":"Nature"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865118308671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865118308671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:51:07Z","timestamp":1760007067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865118308671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0733865118308671"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2018.08.008","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Pharmacotherapy for Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2018.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}